trikafta approv five month pdufa anticip adopt
drive strong revenu growth consult anticip het min
therapi ye trikafta market decreas discount rate
dcf increas dcf-base price target
vertex trikafta approv five month earli octob think
adopt rapid contribut strong perform driven primarili
uptak het min patient though perhap aid use treatment-na
homozyg patient major physician survey
therapeut confer estim least het min patient would
trikafta therapi within month approv even rel conserv assumpt
suggest least het min revenu add revenu growth like
switch orkambi/symdeko patient trikafta given latter modestli higher price
franchis growth recently-reimburs territori eg england cf franchis
estimate assum revenu growth q/q appear reason
project y/i revenu growth street consensu assum y/i
expect re-acceler franchis sale driven trikafta
uptak het min patient arent current take medicin gradual
switch trikafta among homozyg patient current receiv orkambi
symdeko associ increas per patient price higher rate complianc
persist trikafta penetr vertex franchis england follow
grant reimburs end
trikafta fda approv decreas discount rate dcf analysi
increas dcf-base price target
trikafta market investor focu increasingli turn vertex pipelin
busi develop particular investor intrigu vertex program
lead candid complet phase healthi volunt phase ii start
data anticip around earli oral small molecul
focal segment glomerulosclerosi fsg also progress
vertex plan initi phase ii trial reduct proteinuria primari
pleas see page report import disclosur
vertex develop portfolio therapi cystic fibrosi breakthrough
treatment cf patient harbor least one allel cftr potenti
kalydeco first approv patient gate partial loss function
mutat orkambi cftr corrector lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
trikefta contain gener corrector well tezacaftor ivacaftor
produc impress ph data appear like improv qualiti life extend
life span patient trikefta fda approv octob
file review model assum cystic fibrosi patient
one vertex therapi drive nearli franchis sale dcf-base price
target
like ema approv trikafta
phase ii data
initi phase ii poc trial
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi symdeko orkambi kalydeco
standard therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener strike phase data
tripl combin regimen incorpor second gener corrector
min patient regimen approv two month fda review octob
appear repres true breakthrough treatment improv qualiti
life extend life span cystic fibrosi world-wide moreov patent
protect late vertex franchis long commerci life
early-stag pipelin includ candid antitrypsin defici pain sickl
cell diseas beta-thalassemia focal segment glomerulosclerosi initi proof-of-
concept data program anticip late earli
vertex leader discoveri develop candid treat
cystic fibrosi vertex develop portfolio therapi cystic fibrosi
standard care treatment cf patient
harbor least one allel vertex first cystic fibrosi commerci
product kalydeco ivacaftor cftr potenti compound
kalydeco approv fda januari patient non-
gate mutat mutat addit residu function
mutat ad label seri supplement approv vertex
subsequ develop regimen contain kalydeco cftr corrector
lumacaftor tezacaftor broaden use beyond partial loss-of-funct
mutat includ cystic fibrosi patient homozyg
mutat orkambi lumacaftor ivacaftor succeed two pivot trial
june approv juli symdeko tezacaftor
ivacaftor produc posit data two phase trial march
fda approv februari european approv came novemb
brand name symkevi improv potenc orkambi
symdeko homozygot effect patient
one copi allel vertex develop second gener
corrector act synergist lumacaftor tezacaftor
complet correct fold defect cftr trikafta
combin tezacaftor ivacaftor second-gener once-daili
corrector produc impress phase data approv
fda octob brief two month review trikafta appear
repres true breakthrough treatment improv qualiti life
extend life span patient cystic fibrosi
world-wide least one copi mutat moreov
second-gener corrector expect patent protect
vertex franchis long commerci life model
assum cystic fibrosi patient one vertex therapi
drive almost franchis sale impli
industry-lead growth dcf-base price target remain
vertex earn preview also publish part cowen earn
preview industri note publish separ morn link
reproduc page follow increas price
target conjunct preview requir
cowen vs street consensu estim
though vertex manag spoken conserv
trikafta launch expect uptak rapid
like exceed consensu estim vertex
associ trikafta approv vertex increas
cf revenu guidanc
impli cf revenu
think rapid uptak trikafta could drive meaning
upsid estim consensu
cowen compani consensu bloomberg
report date thursday januari close vertex hold confer call
et
earn summari vertex trikafta approv five month earli octob
think adopt rapid contribut strong
perform driven primarili uptak het min patient though perhap aid
use treatment-na homozyg patient think expans
franchis make fastest grow larg cap biotech next
sever year trikafta market investor focu increasingli turn
vertex pipelin busi develop particular investor intrigu
vertex program lead candid complet phase healthi
volunt phase ii start data anticip around earli
expect vertex stock outperform next month trikafta
launch vertex financi result exceed consensu expect vertex pipelin
trikafta fda approv decreas discount rate dcf
analysi increas dcf-base price target
ep estim unchang
financi guidanc expect revenu growth strong project
y/i street consensu assum y/i driven launch trikafta
expect re-acceler franchis growth driven trikafta
uptak het min patient arent current take vertex medicin gradual
switch trikafta among homozyg patient current receiv orkambi
symdeko associ increas per patient price higher rate
complianc persist trikafta penetr vertex franchis
england follow grant reimburs end
non-gaap ep estim y/i consensu
y/i project vrtx corpor tax rate increas
suspect vertex issu rel conserv guidanc
therefor think investor satisfi guidanc bracket consensu
call discuss topic expect vertex confer call focu
datapoint trikafta launch us trend uptak kalydeco
orkambi symdeko recently-reimburs territori pipelin develop
includ vrtx fsg program vertex busi develop
octob vertex announc fda approv trikafta
elexacaftor/tezacaftor/ivacaftor treatment cystic fibrosi cf patient
age year older least one mutat approv came
approxim five month trikafta march pdufa two month
accept nda august approv base data
phase trial patient one mutat one minim
function mutat het min data patient two
mutat vertex submit ema well phase studi trikafta
cf patient age on-going vertex plan conduct addit trial
children year old
approv mark first time het min patient approxim
peopl age medicin treat underli caus diseas
vertex estim anoth approxim cf patient current elig
one compani fda-approv cf medicin also elig
trikafta becam avail market within week approv
vertex disclos trikafta price annual basi per
pack due drug earli approv vertex increas net product
revenu guidanc previous
though consid trikafta launch possibl approv came ahead
even hope expect kalydeco anoth drug consid
breakthrough treatment cf also approv approxim three
month fda review though initi approv far smaller patient
popul view fda rapid review trikafta anoth strong indic
drug clear benefit cystic fibrosi patient furthermor label broad
allow uptak among studi phase trial het min
homozyg patient also patient one mutat one
gate mutat though latter group patient well treat kalydeko
broad label would allow even patient switch
expect initi trikafta uptak come het min patient current
take vertex medicin somewhat gradual switch trikafta among
homozyg patient current receiv orkambi symdeko gate
mutat patient kalydeco vertex earn suggest approxim cf
patient treat orkambi treat
symdeko patient switch orkambi wac see
increas net revenu per patient base compar wac meanwhil patient
switch symdeko vertex see increas net
revenu per patient addit expect patient trikafta higher rate
complianc vs orkambi persist drug increas
averag revenu per patient
cowen compani confer
associ trikafta approv vertex increas cf revenu guidanc
impli cf revenu
cf revenu estim q/q y/i consensu
vertex manag spoken conserv trikafta launch cite barrier
number cf treatment center nonetheless drug break
efficaci subset cf patient therapeut option suggest
uptak rapid exceed consensu estim vertex guidanc
major physician survey confer
estim least het min patient would trikafta therapi within
month approv one assum physician overli optimist
percentag point eg within month treatment
initi spread evenli year would suggest initi therapi
per month approxim het min patient age
would suggest approxim new patient start per month start
therapi novemb anoth decemb vertex would sold
day trikafta pack assum gross net complianc
would equat increment revenu
cf franchis estim assum revenu growth q/q
appear reason conserv given like adopt trikafta
preced figur includ growth switch patient lower price
regimen trikafta increas use rest vertex therapi outsid
safeti profil expand vertex penetr homozyg
market combin sale symdeko orkambi
q/q compar orkambi symdeko sale
y/i
symdeko launch propel rapid growth vrtx franchis past year
half howev seventh full quarter symdeko
market februari fda approv launch matur bottom
end initi cf revenu guidanc increas
associ earli approv trikaftacould met
addit q/q growth cf franchis revenu top-end impli approx q/q
growth manag prior guidanc account potenti market
expans increas symdeko uptak among patient age fda
approv june addit label expans kalydeco label expand
includ children age month august orkambi label also expand
august includ homozyg children age year peopl
 manag previous indic full penetr
homozyg popul like reach
combin orkambi/symdeko/trikafta estim q/q
y/i consensu q/q y/i anticip rapid trikafta
launch addit new patient start therapi england scotland
recent reimburs agreement see think estim
consensu appear achiev conserv
new fund agreement achiev expect continu drive ex-u
revenu fund agreement establish
germani scotland septemb england octob
reimburs germani children age vertex agreement
scotland give cf patient access orkambi symkevi
opportun notabl earli octob vertex announc formal reimburs
agreement england nation health servic nh allow elig cf
patient england access orkambi symkevi expand access kalydeco
medic becam avail england prior novemb vertex
expect elig patient initi therapi persist rang
base term recent reimburs deal england
estim annual kalydeco orkambi symkevi sale england would approxim
assum adopt rel consist pace year
follow avail perhap patient may initi therapi
decemb would impli increment revenu much
growth anticip next year
symkevi symdeko eu brand name receiv market approv novemb
gener sale sale
symkevi indic popul
orkambi wit impress uptak persist europ ireland
netherland particular thu patient initi symkevi eu
switch orkambi believ initi uptak continu
countri sign portfolio reimburs agreement vertex
ireland denmark australia netherland well germani though
histor germani slow adopt orkambi vertex earn call
manag note symkevi launch germani continu strong
demand treatment-nav patient switch orkambi
ex-u sale symkevi orkambi light symkevi
on-going launch recent uk fund agreement think ex-u revenu
like
mutat vertex record kalydeco sale q/q y/i
suspect kalydeco fulli penetr popul patient residu
function mutat fda approv may august continu
lose small number patient symdeko follow launch
estim q/q y/i consensu q/q
oper expens project oper expens q/q
y/i note includ up-front payment crispr
ep project ep compar consensu non-
gaap basi project ep versu consensu
invest thesi vertex leader develop candid treat
cystic fibrosi estim cystic fibrosi patient one
vertex therapi drive almost franchis sale base promis
trikafta project revenu compound-annual-growth-rate non-gaap
ep compound-annual-growth-rate highest larg cap biotech moreov trikafta expect
patent protect vertex franchis long commerci
life addit anticip potenti non-cf pipelin becom
clear next month poc data read-out fg
think fundament posit vertex must biotech larg cap
growth investor expect vertex stock outperform next month
cystic fibrosi portfolio drive industry-lead revenu ep growth
look possibl initi phase ii poc studi
approv symkevi eu patient age
initi phase ii poc trial fsg
like releas data phase ii tezacaftor
possibl ema approv trikafta
file fda approv trikafta patient age
possibl in-licens acquisit addit product candid
addit data sickl cell diseas beta thalassemia
advanc two new compound clinic develop
phase ii data first corrector
advanc cell therapi type diabet clinic develop
cowen compani
earli
cowen compani
statesnumb patient diagnos patient penetr patient kalydeco per patient patient gate gate penetr patient kalydeco per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/trikafta cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling interestnet lncome exclud soe exclud soe expens net share share stock option expens cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu market cf product forecast
sale thisfranchis difficult outlook could alter new safety/
efficaci find emerg competit alter medic treatment paradigm
chang pricing/reimburs environ vertex stock price could also
affect chang outlook key pipelin program includ
evalu market potenti drug yet approv
